Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
co decrease » _ decrease (Expand Search), nn decrease (Expand Search), c decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
co decrease » _ decrease (Expand Search), nn decrease (Expand Search), c decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
2381
-
2382
-
2383
-
2384
-
2385
-
2386
-
2387
Expression of proteins significantly correlated with stereotypy severity in CD1 Mice (n = 28).
Published 2025“…Expression of 7 proteins significantly correlated with stereotypy severity in CD1 mice. …”
-
2388
Changes in Mf (A and B) CFA (C and D) prevalence at baseline, 1, 2 and 3 years after starting MDA.
Published 2025Subjects: -
2389
-
2390
-
2391
-
2392
-
2393
Amplitude for A/L = 0.29.
Published 2025“…By increasing the surface roughness of the bluff body, the lock-in region decreases and as a result, the harvested power from that bluff body is reduced. …”
-
2394
Amplitude for A/L = 0.338.
Published 2025“…By increasing the surface roughness of the bluff body, the lock-in region decreases and as a result, the harvested power from that bluff body is reduced. …”
-
2395
Amplitude for A/L = 0.02.
Published 2025“…By increasing the surface roughness of the bluff body, the lock-in region decreases and as a result, the harvested power from that bluff body is reduced. …”
-
2396
Amplitude for A/L = 0.03.
Published 2025“…By increasing the surface roughness of the bluff body, the lock-in region decreases and as a result, the harvested power from that bluff body is reduced. …”
-
2397
AUC of various models to predict imeglimin efficacy for liver function evaluated by ROC curves.
Published 2025Subjects: -
2398
-
2399
Comparison in baseline variables between efficacy group and non-efficacy group.
Published 2025Subjects: -
2400